We are live on ! Find out more
PHXM

PHAXIAM Therapeutics S.A.. American Depositary Shares

Delisted

PHXM was delisted on the 8th of March, 2024.

10 hedge funds and large institutions have $101M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
10
Holders Change
+10
Holders Change %
% of All Funds
0.23%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$68M +$73M +309,007 New
BI
2
BVF Inc
California
$13.8M +$14.8M +62,500 New
NMC
3
NEA Management Company
Maryland
$13.8M +$14.8M +62,500 New
SFM
4
Sphera Funds Management
Israel
$2.64M +$2.83M +12,000 New
DG
5
Delek Group
Israel
$1.54M +$1.65M +7,000 New
Millennium Management
6
Millennium Management
New York
$959K +$1.03M +4,357 New
Jane Street
7
Jane Street
New York
$607K +$645K +2,734 New
UBS Group
8
UBS Group
Switzerland
$36K +$38.7K +164 New
EDRH
9
Edmond de Rothschild Holding
Switzerland
$13K +$13.5K +57 New
Macquarie Group
10
Macquarie Group
Australia
$13K +$14.2K +60 New

PHXM Hedge Fund Activity: Q4 2017 in Review

10 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q4 2017, worth a combined $101M.

Buyers outnumbered sellers: 10 funds opened new PHXM positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $73M.

  • 10 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q4 2017, up from 0 in Q3 2017.
  • Funds reported $101M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q4 2017.
  • 10 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q4 2017 and 0 closed out, a net change of +10 holders.
  • The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q4 2017 was Baker Bros. Advisors, an estimated $73M added.

Based on aggregated 13F filings for Q4 2017.